GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
last added cars
2022-10-25| Trials & Approvals

AstraZeneca’s Treatment for Rare Throat Disease, Eosinophilic esophagitis, Fails Primary Endpoint

by Max Heirich
Share To

AstraZeneca announced that its clinical trial evaluating a treatment for the rare disease Eosinophilic esophagitis did not meet one of its two primary endpoints. The treatment, Fasenra (benralizumab), demonstrated inferior results in dysphagia symptom reduction compared to the placebo. 

Related Article: Bristol Myers Squibb’ sNDA for Rare Heart Disease Treatment Accepted by the FDA

One out of Two Primary Endpoints Met

Eosinophilic esophagitis is a rare chronic disease characterized by inflammation of the esophagus. The disease is caused by the presence of a kind of white blood cell known as eosinophils in the esophagus. Symptoms include difficulty swallowing (dysphagia), pain, food getting stuck, and anxiety.

AstraZeneca initiated the Phase 3 MESSINA clinical trial, examining the usage of Fasenra as a treatment for the rare disease. The monoclonal antibody binds to the eosinophils’ IL-5 receptor, inducing programmed cell death through the rapid and near-complete depletion of blood and tissue in the white blood cells. Fasenra currently holds an approval as an add-on maintenance treatment for Severe Eosinophilic Asthma in the United States, European Union, and Japan, as well as other countries. 

The Phase 3 trial had two primary endpoints: improvement in histological disease remission and a reduction in dysphagia symptoms. Although MESSINA demonstrated a “significant improvement” in histological disease remission, compared to the placebo, it did not see similar results in improving dysphagia symptoms.

On the results, Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D at AstraZeneca, said, “The results from the MESSINA Phase 3 trial in eosinophilic esophagitis confirm that Fasenra achieved near complete depletion of tissue eosinophils, consistent with its mechanism of action. However, this did not translate into an improvement in dysphagia symptoms. We will continue to analyze the complete data set to share with the scientific community.”

Despite falling short of one of its primary endpoints, the MESSINA trial demonstrated a safety and tolerability profile consistent with the known profile of the medicine.

Going forward, AstraZeneca intends to present the full results of the clinical trial at an upcoming medical meeting. It is unknown if the company intends on moving forward with continue testing of the treatment. 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Novo Nordisk Bets Big on CagriSema With A Heavyweight Move Planned for 2026
2025-02-07
AstraZeneca & Daiichi Sankyo Voluntarily Withdraw EU Submission for Lung Cancer Drug
2024-12-26
M&A
Big Pharma’s Next Move: BMS, Merck, Amgen Eye M&A to Tackle Patent Expirations
2024-11-14
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
Scroll to Top